Related Experiment Videos
Effects of moxalactam and cefotaxime on rabbit renal tissue
Abstract:
To determine and compare the effects of moxalactam and cefotaxime on kidneys, we gave these drugs in doses of 750 and 1,500 mg/kg to rabbits for 7 days. Cephaloridine was included as a positive control. Neither moxalactam nor cefotaxime at either dose caused lysosomal enzymuria, changes visible by light microscopy or increased plasma creatine. Both drugs caused minor alterations in glomerular ultrastructure at the higher dose. Cephaloridine, on the other hand, caused widespread renal functional and morphological damage. We conclude that in rabbits, both moxalactam and cefotaxime are remarkably nonnephrotoxic.
Insights
Moxalactam and cefotaxime showed minimal kidney effects in rabbits, unlike cephaloridine. These antibiotics are remarkably nonnephrotoxic, indicating a favorable safety profile for kidney function.
Area of Science:
- Pharmacology
- Nephrology
- Toxicology
Background:
- Newer cephalosporins like moxalactam and cefotaxime are increasingly used.
- Assessing their renal safety is crucial for clinical application.
Purpose of the Study:
- To compare the nephrotoxic potential of moxalactam and cefotaxime.
- To evaluate renal effects at different dosage levels in a rabbit model.
Main Methods:
- Rabbits received moxalactam or cefotaxime (750 and 1,500 mg/kg) or cephaloridine (control) for 7 days.
- Kidney function was assessed via lysosomal enzymuria and plasma creatine.
- Renal morphology was examined using light microscopy and glomerular ultrastructure analysis.
Main Results:
- Moxalactam and cefotaxime did not induce lysosomal enzymuria, increase plasma creatine, or cause light microscopic damage.
- Minor glomerular ultrastructural changes were observed at the higher dose of both drugs.
- Cephaloridine induced significant renal functional and morphological damage.
Conclusions:
- Moxalactam and cefotaxime demonstrate a remarkable lack of nephrotoxicity in rabbits.
- These findings suggest a favorable renal safety profile for these antibiotics.